Plunkett Research Online: Mereo BioPharma Group

MEREO BIOPHARMA GROUP (MREO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad.....



Mereo BioPharma Group
Ticker: MREO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 44 3330237300
Fax:
Address: One Cavendish Place
4th Floor
London, W1G 0QF United Kingdom

Map
Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
Contacts Description
Denise Scots-Knight CEO/Director
Peter Fellner Chairman of the Board/Director
See More
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad.....See More See More

Auditor: BDO LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (GBP) Bonus (GBP)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: